Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

Clinical trial NCT07004335 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07004335
Sponsor: Hebei Medical University Fourth Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

PD-(L)1 CTLA-4 Advanced Melanoma Iparomlimab Tuvonralimab Bevacizumab

Start date: 2025-07-01
Primary completion: 2028-12-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.